Shark Tank’s Anupam Mittal warns against Ozempic misuse for quick weight loss
Anupam Mittal, founder of People Group and judge on Shark Tank India, has raised concerns about the growing use of diabetes drug Ozempic for weight loss. He warned that treating the medication as a quick fix could encourage unhealthy habits instead of sustainable lifestyle changes. His comments come as Indian drugmakers prepare for a surge in demand once key patents expire in 2026.
Mittal acknowledged the importance of GLP-1 drugs like Ozempic for patients with diabetes, obesity, and metabolic disorders. However, he stressed that using the medication purely for cosmetic weight loss risks normalising shortcuts over long-term health efforts.
The patent expirations will allow Indian companies to expand their share of the Ozempic market. With generic production set to begin, prices may drop, increasing accessibility. Mittal’s warning, however, highlights the need for careful regulation and public awareness about the drug’s intended medical use.
